MedPath

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000791
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with zidovudine (AZT) versus AZT alone. To determine the influences of viral phenotype on the anti-HIV activity of these treatment regimens.

SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve the benefits of both drugs in patients with HIV infection.

Detailed Description

SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve the benefits of both drugs in patients with HIV infection.

Patients are randomized to receive AZT alone or in combination with one of two doses of SC-49483, administered three times daily. Treatment continues for 16 to 24 weeks. Per 07/19/94 amendment: At the end of 24 weeks, blinded treatment continues for an additional 4 weeks, at which time patients may receive open-label drug on an optional basis for 90 days.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
210
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

Alabama Therapeutics CRS

🇺🇸

Birmingham, Alabama, United States

USC CRS

🇺🇸

Los Angeles, California, United States

Stanford CRS

🇺🇸

Palo Alto, California, United States

Ucsf Aids Crs

🇺🇸

San Francisco, California, United States

University of Colorado Hospital CRS

🇺🇸

Aurora, Colorado, United States

Univ. of Miami AIDS CRS

🇺🇸

Miami, Florida, United States

Northwestern University CRS

🇺🇸

Chicago, Illinois, United States

Rush Univ. Med. Ctr. ACTG CRS

🇺🇸

Chicago, Illinois, United States

Weiss Memorial Hosp.

🇺🇸

Chicago, Illinois, United States

Cook County Hosp. CORE Ctr.

🇺🇸

Chicago, Illinois, United States

Scroll for more (12 remaining)
Alabama Therapeutics CRS
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.